Advertisement

Topics

Swissmedic accepts review of Takeda and TiGenix’s file on Cx601

19:00 EDT 20 Jun 2017 | Pharmaceutical Technology

The Swiss Agency for Therapeutic Products (Swissmedic) has accepted a review of Takeda and TiGenix’s file on investigational compound Cx601 for the treatment of complex perianal fistulas in patients with Crohn's disease.

Original Article: Swissmedic accepts review of Takeda and TiGenix’s file on Cx601

NEXT ARTICLE

More From BioPortfolio on "Swissmedic accepts review of Takeda and TiGenix’s file on Cx601"

Advertisement
Quick Search
Advertisement
Advertisement